First FDA-Approved Pill for Children 4–11 With APDS

Joenja (leniolisib) is an oral kinase inhibitor (PI3Kδ inhibitor). On the US Prescribing Information (revised 09/2026) it is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater.

On 11 September 2026, a supplemental expansion added ages 4–11 (with weight floor 27 kg) and new tablet strengths 40 mg and 50 mg. Joenja was first approved in 2023 for APDS in patients 12 years and older.

Distinct path — not this label: Sirolimus / other immunosuppressants used off-label in APDS are not this labelled Joenja tablet. A separate company sNDA for children 4–11 weighing 13 to <27 kg is described in company materials as submitted / pending — not this approved pathway. Today’s approved US oral Joenja treatment pathway for APDS ages 4+ weighing ≥27 kg is Pharming Joenja (NDA 217759, including S-006).

The FDA approved supplemental NDA 217759/S-006 effective 11 September 2026. Letter addressee: Jennifer Knicley, Senior Director, Global Regulatory Affairs, Pharming Technologies B.V. / Warren, NJ address on letter. Letter signed Kelly Stone, MD, PhD (electronic signature KELLY D STONE 09/11/2026 11:32:29 AM). Supplement provides expansion to pediatric patients 4 years and older who weigh 27 kg or greater and addition of 40 mg and 50 mg tablets. USPI Reference ID 5867450. Manufactured for Pharming Healthcare Inc., 10 Independence Blvd., Warren, NJ 07059.

Where this is taking place

Approved prescription route today: United States — FDA-labelled Joenja for APDS in patients 4+ weighing ≥27 kg, prescribed through an immunology / genetics / rare-disease clinic experienced with APDS, with specialty pharmacy and APDS Assist navigation. Company materials state newly approved pediatric doses are expected to be available to eligible US pediatric patients in October through the established specialty distribution network. This is a prescription rare-disease conversation — not a cure, not a DIY genetic treatment, and not a DIY import.

Outside the United States: At the time of writing, authorisation of this specific ages 4–11 / 40–50 mg expansion by Health Canada, EMA/EC, MHRA, TGA, Swissmedic, or PMDA/MHLW is not confirmed. Do not import on your own.

Study 2201 — NCT02435173 — 12-week randomized, placebo-controlled study in adults and pediatric patients 12 years and older with confirmed APDS-associated PI3Kδ mutation (PIK3CD or PIK3R1). Co-primary endpoints (lymphadenopathy SPD and naïve B-cell percentage) were statistically significant. This remains the efficacy backbone for patients 12+ on the label.

Study LE3301 — NCT05438407 — Single-arm, open-label safety and pharmacokinetic study in pediatric patients 4 to less than 12 years with APDS. USPI: 8 patients aged 4 to less than 12 who weigh ≥27 kg received the recommended weight-based dosage; PK showed no clinically significant difference vs older patients; safety consistent with older cohorts, with additional common ARs abdominal pain, cough, and respiratory tract infection.

Labelled commercial supply for eligible US children ≥27 kg is the access route. That is not open enrolment into LE3301 as a new pivotal cohort. ClinicalTrials.gov lists LE3301 as active but no longer taking new patients. Commercial supply is also not approval for children under 4 or under 27 kg.

The practical prescription route in the US is an APDS-experienced immunology / genetics clinician who can confirm the genetic diagnosis, verify age/weight eligibility, check pregnancy status when relevant, review drug interactions (strong CYP3A inhibitors/inducers; BCRP/OATP substrates), and enroll the family in APDS Assist if appropriate.

Approval matrix

Access by country

• United States: Ask an immunology / genetics / APDS-experienced clinician about FDA-labelled Joenja for a child 4–11 who weighs ≥27 kg. Labelled expansion 11 September 2026. Path: confirm APDS genetic diagnosis → verify pregnancy status when relevant → weight-based oral dose twice daily (~12 hours apart), with or without food → specialty pharmacy / APDS Assist. Missed dose: if more than 6 hours late, skip and take the next dose at the usual time. If vomiting within 1 hour, take another dose as soon as possible. Bottles of 60: NDC 71274-140-60 (40 mg), 71274-150-60 (50 mg), 71274-170-60 (70 mg). Store 20–25 °C (excursions 15–30 °C); do not refrigerate. Suspected adverse reactions: Pharming Healthcare 1-800-930-5221 or FDA MedWatch 1-800-FDA-1088. Patient support: APDS Assist — 1-877-796-2737 (Mon–Fri 8 AM–8 PM ET) or APDSAssist@pantherxrare.com / joenja.com/apds-assist. No list price or copay dollars in this article. This is US labelled commercial supply, not a DIY import.

• Canada: Confirm whether the Canadian Product Monograph includes ages 4–11 and 40/50 mg strengths. If not, ask what legal Canadian paths exist.

• European Union / United Kingdom / Australia / Japan / other countries: Authorisation of this pediatric expansion not confirmed on the sources checked. Do not import on your own.

• If your regulator has not authorised this age/strength pathway: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a labelled-country centre, or waiting.

Who is eligible (from the US label)

This is an APDS conversation for patients 4 years and older weighing ≥27 kg — not established under age 4 or under 27 kg.

United States (USPI, revised September 2026):

• Indication: Treatment of APDS in adult and pediatric patients 4 years of age and older who weigh 27 kg or greater.
• Recommended dosage (oral, ~12 h apart, with/without food):

• Before start: Verify pregnancy status in females of reproductive potential.
• Contraindications: None (USPI §4).
• Warnings: Embryo-fetal toxicity; live attenuated vaccines may be less effective; hypersensitivity including anaphylaxis (discontinue and treat if occurs). Avoid strong CYP3A4 inhibitors; avoid strong/moderate CYP3A4 inducers; avoid BCRP, OATP1B1, and OATP1B3 substrates.
• Hepatic impairment: Moderate to severe — not recommended.
• Most common ARs (>10%): Ages 12+: headache, sinusitis, atopic dermatitis. Ages 4–<12 (≥27 kg): abdominal pain, cough, respiratory tract infection.
• Lactation: Advise women not to breastfeed during treatment and for 1 week after the last dose.
• Not established: Younger than 4 years or weight less than 27 kg.

Not labelled on the sources checked for this article:

• Children <4 years or <27 kg (company notes a separate lower-weight sNDA — not this label).
• Treating LE3301 / NCT05438407 as open commercial enrolment.
• Automatic match of foreign Joenja labels to this US ages 4–11 pathway.

What the studies showed (USPI)

Study 2201 — NCT02435173 (ages 12+ efficacy):

• Randomized 2:1 Joenja 70 mg BID (N=21) vs placebo (N=10) for 12 weeks.
• Co-primary: log10 SPD of index lesions difference vs placebo −0.25 (p 0.0006); naïve B cells % difference 37.30 (p 0.0002) in the analysed subsets described on USPI.

Study LE3301 — NCT05438407 (ages 4–<12 safety/PK):

• Open-label; USPI safety/PK for the labelled weight band: 8 patients 4 to <12 years weighing ≥27 kg received recommended weight-based doses for at least 12 weeks (up to 24 weeks).
• PK: no clinically significant difference vs patients 12+.
• Additional common ARs in this pediatric band: abdominal pain, cough, respiratory tract infection.

How to talk with a doctor

Bring this page and ask an APDS-experienced immunology / genetics clinician:

1. “Does my child have genetically confirmed APDS, and do they weigh at least 27 kg?”
2. “Is labelled US Joenja the right dose (40 / 50 / 70 mg twice daily) for their weight and age?”
3. “How do we enroll in APDS Assist for specialty pharmacy and coverage navigation?”
4. “What vaccines and other medicines need review before starting?”
5. If outside the US: “Has our regulator authorised Joenja for ages 4–11, or what legal options exist?”

Who is involved (from primary sources)

• Sponsor / manufacturer: Pharming Technologies B.V. / Pharming Healthcare Inc., Warren, NJ.
• FDA letter contact on S-006: Jennifer Knicley (applicant attention); Kelly Stone, MD, PhD (signing official).
• Pivotal / supporting studies: Study 2201 (NCT02435173); Study LE3301 (NCT05438407).
• Patient support (company): APDS Assist — 1-877-796-2737; AE line 1-800-930-5221.

Names and roles above are limited to what appears on the primary sources cited. Contacts not listed on those sources are omitted.

Primary sources

1. FDA USPI — JOENJA (leniolisib) tablets — Revised 09/2026; NDA 217759; Reference ID 5867450 — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217759s006lbl.pdf
2. FDA supplement approval letter — NDA 217759/S-006 — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217759Orig1s006ltr.pdf
3. FDA news: FDA approves first treatment for children aged 4–11 years with APDS — content current as of 09/11/2026 — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system
4. ClinicalTrials.gov — NCT02435173 (Study 2201); NCT05438407 (pediatric 4–11 / LE3301)
5. APDS Assist — https://joenja.com/apds-assist/

Not medical advice. Talk with a clinician who knows the full history before any treatment decision. Authorized is not funded.